Zacks Research Has Positive Outlook for BPMC Q1 Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Stock analysts at Zacks Research lifted their Q1 2025 EPS estimates for Blueprint Medicines in a report released on Wednesday, March 5th. Zacks Research analyst A. Chakraborty now forecasts that the biotechnology company will post earnings per share of ($0.76) for the quarter, up from their previous estimate of ($0.85). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Blueprint Medicines’ Q2 2025 earnings at ($0.64) EPS, Q3 2025 earnings at ($0.50) EPS, FY2025 earnings at ($2.13) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at $0.16 EPS, Q3 2026 earnings at $0.21 EPS and FY2026 earnings at $0.50 EPS.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%.

Several other analysts also recently commented on the stock. Piper Sandler raised their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. JMP Securities restated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Guggenheim restated a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. HC Wainwright restated a “buy” rating and set a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, February 14th. Finally, StockNews.com downgraded shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and a consensus price target of $125.21.

Blueprint Medicines Stock Down 1.6 %

Shares of BPMC stock opened at $87.12 on Friday. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of -80.67 and a beta of 0.62. Blueprint Medicines has a one year low of $80.68 and a one year high of $121.90. The company’s fifty day moving average price is $99.43 and its 200-day moving average price is $94.27. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80.

Institutional Investors Weigh In On Blueprint Medicines

Institutional investors have recently made changes to their positions in the company. Quarry LP bought a new stake in Blueprint Medicines during the 3rd quarter valued at about $32,000. R Squared Ltd bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $51,000. Covestor Ltd raised its holdings in shares of Blueprint Medicines by 206.7% in the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 403 shares in the last quarter. Headlands Technologies LLC bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $65,000. Finally, Thematics Asset Management bought a new stake in shares of Blueprint Medicines in the 4th quarter valued at about $72,000.

Insiders Place Their Bets

In other news, insider Ariel Hurley sold 3,203 shares of the firm’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $92.62, for a total value of $296,661.86. Following the completion of the sale, the insider now owns 18,270 shares in the company, valued at approximately $1,692,167.40. This trade represents a 14.92 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the completion of the sale, the chief executive officer now owns 149,378 shares of the company’s stock, valued at $16,467,430.72. This trade represents a 0.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 48,427 shares of company stock valued at $4,837,801 in the last three months. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.